MarketBotsLab
Watchlist

BBIO

BridgeBio Pharma

Pharmaceutical Preparations · Health Care

$74.03-1.29%

Quote via Yahoo Finance, may be delayed · 2026-11-03 · 4:00 PM ET

Daily prices: Yahoo Finance, split-adjusted. As of 2026-11-03.

Drag across the line to read a price. Dots mark earnings, filings and dividends.

Very weak profile

Revenue CAGR, 3Y lifts this profile the most.

As of 2025-12-31. Latest quarter ended 2026-09-30. v1 methodology, subject to change.

The profile score is 7 points lower since last quarter. Momentum is 31 points lower. Cash is 27 points higher.

Sector rank 45 of 46

In plain English

  • BridgeBio Pharma operates in Pharmaceutical Preparations.
  • Latest-year revenue was 0.5 billion.
  • The profile score is 27, a Very weak profile. Growth is the strongest listed input.

Written from the figures on this page. No language model was called. It may still be wrong. Not advice.

Report an error

As of 2025-12-31. Latest quarter ended 2026-09-30. SEC EDGAR companyfacts, fetched 2026-11-01. SEC filing

Financials

$70M21$78M22$9M23$222M24$502M25

Tap a column to read the value.

See full statements

P/E vs own history

Not shown while earnings are negative.

Earnings

Actual earnings per share from EDGAR filings. Historical estimates are not used.

-0.30-1.3824-1226-09

Actual from EDGAR

Data confidence

The Company Score summarises financial characteristics relative to similar companies using a published formula. It does not predict future returns.

SEC EDGAR companyfacts, fetched 2026-11-01.

Peers

Peers share the industry and sit between 0.25× and 4× the market cap.

CompanyScoreRev growthOp marginP/ENet debt / EBITDA
BBIO27126%-104%—12.0x
ZTS682%47%14.01.3x
ALNY5665%14%68.6-1.2x
VTRS41-3%-19%—4.5x
INSM2367%-206%—12.0x